Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

86.66USD
12:50pm EST
Change (% chg)

$0.21 (+0.24%)
Prev Close
$86.45
Open
$86.56
Day's High
$86.83
Day's Low
$86.07
Volume
214,772
Avg. Vol
887,261
52-wk High
$89.01
52-wk Low
$67.42

Latest Key Developments (Source: Significant Developments)

‍Kymera Therapeutics announces $30 mln series A financing round​
Monday, 30 Oct 2017 07:00am EDT 

Oct 30 (Reuters) - :‍Kymera Therapeutics Llc announces $30 million series a financing round​.‍Kymera Therapeutics Llc - financing round was led by Atlas Venture, along with Lilly Ventures and Amgen Ventures​.  Full Article

Lilly "very optimistic" on U.S. prospect for arthritis drug
Tuesday, 24 Oct 2017 10:35am EDT 

Oct 24 (Reuters) - Eli Lilly And Co :Eli Lilly says "very optimistic" on U.S. prospect for arthritis drug baricitinib; still sees resubmission to FDA by January.  Full Article

Eli Lilly reports Q3 EPS $0.53
Tuesday, 24 Oct 2017 06:25am EDT 

Oct 24 (Reuters) - Eli Lilly And Co :Lilly reports third-quarter results, announces strategic review of Elanco Animal Health.Q3 earnings per share $0.53.Sees FY 2017 revenue $22.4 billion to $22.7 billion.Q3 revenue $5.658 billion versus I/B/E/S view $5.52 billion.Q3 earnings per share view $1.03 -- Thomson Reuters I/B/E/S.Sees FY 2017 non-GAAP earnings per share $4.15 to $4.25.Sees FY 2017 earnings per share $1.73 to $1.83.‍Reviewing strategic alternatives for Elanco Animal Health, including an initial public offering, merger, sale​.‍For Q3 of 2017, Alimta generated worldwide revenue of $514.5 million, which decreased 10 percent compared with Q3 of 2016​.Qtrly ‍non-GAAP eps $1.05​.Qtrly Cymbalta sales $‍​183.2 million versus $313.5 million.‍Company's worldwide Jardiance revenue during Q3 of 2017 was $127.2 million, an increase of 168 percent compared with Q3 of 2016​.‍Review of strategic alternatives for Elanco Animal Health may also include retention of the business.FY2017 earnings per share view $4.16, revenue view $22.51 billion -- Thomson Reuters I/B/E/S.‍In Q3 of 2017, company recognized asset impairment, restructuring and other special charges of $406.5 million​.Co will provide an update on ​‍review of strategic alternatives for Elanco Animal Health no later than middle of 2018.‍Is exploring strategic options for Posilac, including seeking a buyer for molecule and its Augusta manufacturing site​.  Full Article

Lilly announces $72 million investment in diabetes manufacturing in Indianapolis
Monday, 23 Oct 2017 06:45am EDT 

Oct 23 (Reuters) - Eli Lilly And Co :Lilly announces $72 million investment in diabetes manufacturing in Indianapolis.Eli Lilly and Co - ‍investment will be used to replace an existing insulin vial filling line and allow Lilly to meet "growing demand" for its insulins​.  Full Article

Eli Lilly ‍declares Q4 dividend of $0.52/share
Monday, 16 Oct 2017 03:32pm EDT 

Oct 16 (Reuters) - Eli Lilly And Co ::Declared a dividend for Q4 of 2017 of $0.52 per share on outstanding common stock​.  Full Article

FDA grants priority review for Lilly's verzenio
Thursday, 12 Oct 2017 06:45am EDT 

Oct 12 (Reuters) - Eli Lilly And Co ::FDA grants priority review for potential new indication for Lilly's verzenio (abemaciclib) as initial treatment of advanced breast cancer.Eli Lilly And Co - ‍FDA's goal is to take action within eight months of receiving an application, compared with standard review timeframe of 12 months​.  Full Article

‍BIOLOGICS SAYS SELECTED BY ELI LILLY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​
Wednesday, 11 Oct 2017 11:21am EDT 

Oct 11 (Reuters) - Biologics Inc::‍BIOLOGICS INC SAYS HAS BEEN SELECTED BY ELI LILLY AND COMPANY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​.  Full Article

Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio
Tuesday, 10 Oct 2017 06:45am EDT 

Oct 10 (Reuters) - Eli Lilly And Co :Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio™ (abemaciclib) in kras-mutated, advanced non-small cell lung cancer.Eli Lilly And Co - ‍lilly will submit data for presentation at a medical meeting in 2018​.Eli Lilly And Co -Phase 3 JUNIPER study evaluating Verzenio​ ‍did not meet its primary endpoint of overall survival.Eli Lilly - ‍however, analysis of secondary study endpoints of both progression-free survival and overall response rate showed evidence of monotherapy activity in abemaciclib arm​.Eli Lilly - ‍control arm in Phase 3 JUNIPER study for Verzenio​ showed higher overall survival rate than expected based on historical data in setting.  Full Article

U.S. PTO rules in Eli Lilly's favor on Alimta
Thursday, 5 Oct 2017 04:13pm EDT 

Oct 5 (Reuters) - Eli Lilly And Co :Patent trial and appeal board of U.S. PTO ruled in company's favor regarding patentability of vitamin regimen for Alimta.In IPR proceedings initiated by Neptune Generics LLC and Sandoz, U.S. PTO found that claims of vitamin regimen patent are valid​.If patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022​.  Full Article

Eli Lilly's ‍Humalog Junior Kwikpen now available by prescription in U.S.​
Wednesday, 4 Oct 2017 09:00am EDT 

Oct 4 (Reuters) - Eli Lilly And Co :Eli Lilly and Co - ‍Humalog Junior Kwikpen now available by prescription for treatment of diabetes in U.S.​.  Full Article

BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS